These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 1699309)

  • 1. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
    Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
    Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
    Uberti J; Martilotti F; Chou TH; Kaplan J
    Blood; 1992 Jan; 79(1):261-8. PubMed ID: 1370206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
    Drobyski WR; LeFever AV; Truitt RL
    Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
    Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Davis R; Ragab AH
    Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
    Soiffer RJ; Ritz J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific recognition of human leukemic cells by allogeneic T cell lines.
    Sosman JA; Oettel KR; Hank JA; Fisch P; Sondel PM
    Transplantation; 1989 Sep; 48(3):486-95. PubMed ID: 2571206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased lymphokine-activated killer cells in kidney transplant recipients. Correlation with a diminished number of CD3-/NKH1+ cells.
    Alard P; Lantz O; Ramirez A; Perrot JY; Chavanel G; Fries D; Charpentier B; Senik A
    Transplantation; 1990 Aug; 50(2):250-7. PubMed ID: 1696407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The graft-vs.-leukemia effect. Implications for post-marrow transplant antileukemia treatment.
    Sosman JA; Sondel PM
    Am J Pediatr Hematol Oncol; 1993 May; 15(2):185-95. PubMed ID: 8498642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.